Pediatric Liposarcoma Questions & Answers

1. Marcus KC, Grier HE, Shamberger RC, Gebhardt MC, Perez-Atayde A, Silver B. Childhood soft tissue sarcoma: a 20-year experience. J Pediatr. 1997 Oct. 131(4):603-7. [QxMD MEDLINE Link].

2. Spunt SL, Poquette CA, Hurt YS, et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol. 1999 Dec. 17(12):3697-705. [QxMD MEDLINE Link].

3. Shmookler BM, Enzinger FM. Liposarcoma occurring in children. An analysis of 17 cases and review of the literature. Cancer. 1983 Aug 1. 52(3):567-74. [QxMD MEDLINE Link].

4. Italiano A, Cardot N, Dupre F, et al. Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the "missing link" between lipomas and liposarcomas?. Int J Cancer. 2007 Jul 15. 121(2):308-15. [QxMD MEDLINE Link].

5. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, et al. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13. 9 (28):19891-19899. [QxMD MEDLINE Link]. [Full Text].

6. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993 Jun 17. 363(6430):640-4. [QxMD MEDLINE Link].

7. Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2007 Jun 15. 109(12):2522-31. [QxMD MEDLINE Link].

8. de Vreeze RS, de Jong D, Nederlof PM, et al. Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience. Ann Surg Oncol. 2010 Mar. 17(3):686-93. [QxMD MEDLINE Link].

9. Castleberry RP, Kelly DR, Wilson ER, et al. Childhood liposarcoma. Report of a case and review of the literature. Cancer. 1984 Aug 1. 54(3):579-84. [QxMD MEDLINE Link].

10. Ferrari A, Casanova M, Spreafico F, et al. Childhood liposarcoma: a single-institutional twenty-year experience. Pediatr Hematol Oncol. 1999 Sep-Oct. 16(5):415-21. [QxMD MEDLINE Link].

11. La Quaglia MP, Spiro SA, Ghavimi F, Hajdu SI, Meyers P, Exelby PR. Liposarcoma in patients younger than or equal to 22 years of age. Cancer. 1993 Nov 15. 72(10):3114-9. [QxMD MEDLINE Link].

12. Alaggio R, Coffin CM, Weiss SW, et al. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age. Am J Surg Pathol. 2009 May. 33(5):645-58. [QxMD MEDLINE Link].

13. Gronchi A, Casali PG, Fiore M, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer. 2004 Jun 1. 100(11):2448-55. [QxMD MEDLINE Link].

14. Cheng EY, Springfield DS, Mankin HJ. Frequent incidence of extrapulmonary sites of initial metastasis in patients with liposarcoma. Cancer. 1995 Mar 1. 75(5):1120-7. [QxMD MEDLINE Link].

15. Schwab JH, Boland PJ, Antonescu C, Bilsky MH, Healey JH. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer. 2007 Oct 15. 110(8):1815-22. [QxMD MEDLINE Link].

16. Antonescu CR, Elahi A, Humphrey M, et al. Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. J Mol Diagn. 2000 Aug. 2(3):132-8. [QxMD MEDLINE Link]. [Full Text].

17. Tornin J, Hermida-Prado F, Padda RS, Gonzalez MV, Alvarez-Fernandez C, Rey V, et al. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway. Neoplasia. 2018 Jan. 20 (1):44-56. [QxMD MEDLINE Link]. [Full Text].

18. Gimber LH, Montgomery EA, Morris CD, Krupinski EA, Fayad LM. MRI characteristics associated with high-grade myxoid liposarcoma. Clin Radiol. 2017 Jul. 72 (7):613.e1-613.e6. [QxMD MEDLINE Link].

19. Song T, Shen J, Liang BL, Mai WW, Li Y, Guo HC. Retroperitoneal liposarcoma: MR characteristics and pathological correlative analysis. Abdom Imaging. 2007 Sep-Oct. 32(5):668-74. [QxMD MEDLINE Link].

20. Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging. 2006 Nov. 33(11):1290-5. [QxMD MEDLINE Link].

21. Yang J, Codreanu I, Servaes S, Zhuang H. Earlier detection of bone metastases from pleomorphic liposarcoma in a pediatric patient by FDG PET/CT than planar 99mTc MDP bone scan. Clin Nucl Med. 2012 May. 37(5):e104-7. [QxMD MEDLINE Link].

22. Enzinger FM, Weiss SW. Liposarcoma. Enzinger F, Weiss S, eds. Soft Tissue Tumors. St Louis, MO: Mosby; 1995. 431-66.

23. Cecchetto G, Alaggio R, Dall'Igna P, et al. Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies. Cancer. 2005 Nov 1. 104(9):2006-12. [QxMD MEDLINE Link].

24. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10. Vol 34:786-93. [QxMD MEDLINE Link]. [Full Text].

25. Baruchel S, Pappo A, Krailo M, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer. 2012 Mar. Vol 48:579-85. [QxMD MEDLINE Link]. [Full Text].

26. Bill KL, Casadei L, Prudner BC, et al. Liposarcoma: molecular targets and therapeutic implications. Cell Mol Life Sci. 2016 Oct. Vol 73:3711-8. [QxMD MEDLINE Link]. [Full Text].

27. Raaf JH, Ragsdale BD. Surgical management of liposarcoma. Bogumil GP, Fleegler EJ, eds. Tumors of the Hand and Upper Limb. 1993.

28. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec. 41(18):2853-60. [QxMD MEDLINE Link].

29. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1. 27(25):4188-96. [QxMD MEDLINE Link].

30. Zijoo R, von Mehren M. Efficacy of trabectedin for the treatment of liposarcoma. Expert Opin Pharmacother. 2016 Oct. 17 (14):1953-62. [QxMD MEDLINE Link].

31. Mahmood ST, Agresta S, Vigil C, et al. Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. Int J Cancer. 2010 Dec 10. [QxMD MEDLINE Link].

32. Brandal P, Bjerkehagen B, Heim S. Rearrangement of chromosomal region 8q11-13 in lipomatous tumours: correlation with lipoblastoma morphology. J Pathol. 2006 Feb. 208(3):388-94. [QxMD MEDLINE Link].

Alexander Gozman, MD Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, Albany Medical Center

Alexander Gozman, MD is a member of the following medical societies: American Medical Association, American Society of Clinical Oncology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Children's Oncology Group

Disclosure: Nothing to disclose.

Anastasios K Konstantakos, MD Clinical Associate Surgeon, Department of Cardiovascular Surgery, Billings Clinic

Disclosure: Nothing to disclose.

Vikramjit S Kanwar, MBBS, MBA, MRCP(UK) Professor Emeritus of Pediatrics, Albany Medical College; Chief of Pediatric Oncology, Homi Bhabha Cancer Hospital, Varanasi, India

Vikramjit S Kanwar, MBBS, MBA, MRCP(UK) is a member of the following medical societies: Children's Oncology Group, Indian Academy of Pediatrics, International Society of Pediatric Oncology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Steven K Bergstrom, MD Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland

Steven K Bergstrom, MD is a member of the following medical societies: Alpha Omega Alpha, Children's Oncology Group, American Society of Clinical Oncology, International Society for Experimental Hematology, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Max J Coppes, MD, PhD, MBA Executive Vice President, Chief Medical and Academic Officer, Renown Heath

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American College of Healthcare Executives, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Disclosure: Nothing to disclose.

Stephan A Grupp, MD, PhD Director, Stem Cell Biology Program, Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia; Associate Professor of Pediatrics, University of Pennsylvania School of Medicine

Stephan A Grupp, MD, PhD is a member of the following medical societies: American Association for Cancer Research, Society for Pediatric Research, American Society for Blood and Marrow Transplantation, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article